Login to Your Account



FDA Approves Guilford's Gliadel As First-Line Therapy For Glioma

By Kim Coghill


Thursday, February 27, 2003
The FDA issued Guilford Pharmaceuticals Inc. approval to expand the use of the Gliadel Wafer as a first-line therapy for patients with high-grade malignant glioma. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription